FIELD: medicine, pharmaceutics.
SUBSTANCE: presented invention refers to using an antibody for producing a medicinal product for treating or preventing Krukenberg's tumours. While binding to an epitope found on D1 loop or D3 CLD18A2 loop, the antibody mediates elimination and/or inhibition of CLD18A2-expressing cell proliferation. What is also described is a version of using the antibody, wherein it is conjugated with a therapeutic agent for growth inhibition and/or elimination of a CLD18A2-expressing cell.
EFFECT: using the invention can find application in medicine when producing a medicinal product for treating or preventing Krukenberg's tumours.
19 cl, 39 dwg, 9 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER | 2008 |
|
RU2682285C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2014 |
|
RU2678700C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6 | 2012 |
|
RU2676731C2 |
